Next Article in Journal
Acute Promyelocytic Leukemia (APL): A Review of the Classic and Emerging Target Therapies towards Molecular Heterogeneity
Next Article in Special Issue
Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy
Previous Article in Journal
Acknowledgment to the Reviewers of Future Pharmacology in 2022
Previous Article in Special Issue
Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine
 
 
Review
Peer-Review Record

Aspirin Therapy, Cognitive Impairment, and Dementia—A Review

Future Pharmacol. 2023, 3(1), 144-161; https://doi.org/10.3390/futurepharmacol3010011
by Elizabeth H. Thong, Edward C. Y. Lee, Choi-Ying Yun, Tony Y. W. Li and Ching-Hui Sia *
Reviewer 1: Anonymous
Reviewer 2:
Future Pharmacol. 2023, 3(1), 144-161; https://doi.org/10.3390/futurepharmacol3010011
Submission received: 30 November 2022 / Revised: 28 December 2022 / Accepted: 3 January 2023 / Published: 1 February 2023
(This article belongs to the Special Issue Feature Papers in Future Pharmacology)

Round 1

Reviewer 1 Report

Mild cognitive impairment MCI and dementia (different types) -   are very frequent in patients with cardiovascular risk factors.

Aspirin is used drug for both primary and secondary prevention in patients with cardiovascular diseases.

The anti-platelet role of low dose of acetylsalicylic acid (75-300 mg/day with COX1 inhibition COX-1 and secondary inhibition of thromboxane A2 synthesis) and the anti-inflammatory role of high dose of acetylsalicylic acid in in preventing cognitive decline are evaluated by the authors.

Studies results are divergent, the majority of trials did not bring undeniable evidence of preventing role of aspirin in cognitive decline, with exception of vascular dementia, cerebral small vessel disease and coronary heart disease patients.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The review is well written and easy to follow.

The format is well organized and described in each impact of aspirin with cognitive decline and dementia.

The references are updated.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop